October 21, 2024

Richard Welch

Richard Welch, Ph.D., leads the chemistry, manufacturing, and controls (CMC) team at IAVI to rapidly advance the most promising vaccine and antibody candidates from the laboratory into clinical trials.

Prior to joining IAVI, Welch was vice president, CMC/operations, at Sirnaomics, where he was responsible for overall CMC and program management leadership for clinical stage oncology and metabolic disease products. Before that, he was vice president, development services, at Emergent BioSolutions, where his portfolio included multiple vaccines for biodefense and infectious disease targets, including a licensed second-generation anthrax vaccine for use in post-exposure prophylaxis, among other products. 

Welch earned a Ph.D. in biochemistry from Rice University.